



## Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

November 9, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 9, 2022-- [Kezar Life Sciences, Inc.](#) (Nasdaq: [KZR](#)), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will participate in two upcoming investor conferences in November.

### Presentation Details:

**Event:** Jefferies London Healthcare Conference

**Location:** London, UK

**Date/Time:** Wednesday, November 16, 2022, at 8:35 AM GMT

**Presenter:** Noreen Roth Henig, M.D., Chief Medical Officer

**Format:** Fireside Chat

**Event:** Evercore ISI 5<sup>th</sup> Annual HealthCONx Conference

**Date/Time:** Wednesday, November 30, 2022, at 12:10 PM ET

**Presenters:** John Fowler, Co-Founder, Chief Executive Officer

**Format:** Fireside Chat

Webcasts from the presentations will be available on the "Events & Presentations" section of the Company's website at [www.kezarlifesciences.com](http://www.kezarlifesciences.com). Following the events, archived webcasts will be available on the Kezar website for 90 days.

### About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company's platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit [www.kezarlifesciences.com](http://www.kezarlifesciences.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20221109005819/en/>

### Investor Contact:

Gitanjali Jain

Vice President, Investor Relations and External Affairs

[gjain@kezarbio.com](mailto:gjain@kezarbio.com)

### Media Contact:

Julia Deutsch

Solebury Strategic Communications

[jdeutsch@soleburystrat.com](mailto:jdeutsch@soleburystrat.com)

Source: Kezar Life Sciences, Inc.